BioTuesdays

Category - News

Entellus Medical
Markets

BTIG starts Entellus Medical at buy

BTIG Research has initiated coverage of Entellus Medical (NASDAQ:ENTL) with a ‘buy” rating and $22 price target. The stock closed at $18.58 on Monday. “Entellus Medical benefits patients, physicians, and payers by...

June 14, 2016
Endologix Logo
Markets

Canaccord upgrades Endologix to buy

Canaccord Genuity has upgraded Endologix (NASDAQ:ELGX) to “buy” from “hold” and raised its price target to $15.50 from $11.25. The stock closed at $12.68 on Friday. The company is developing Nellix as an endovascular...

June 13, 2016
Vital Connect
Developments

Vital Connect closes new financing round

Closely-held Vital Connect, a leader in medical-grade wearable biosensor systems, has closed a term loan facility of $17.5-million with Perceptive Advisors, of which $10-million was funded at the initial closing today...

June 13, 2016
GenMark Diagnostics
Markets

Canaccord ups GenMark price target to $10.50

Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday. After the close yesterday, GNMK announced a major milestone, achieving CE...

June 9, 2016
fibrocell
Developments

Fibrocell Phase 2 vocal scaring trial fails

A Phase 2 clinical trial of Fibrocell Science’s (NASDAQ:FCSC) azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia failed to meet its primary endpoints. Fibrocell intends to focus...

June 8, 2016
Biocept Logo
Markets

Roth starts Biocept at buy

Roth Capital Partners has initiated coverage on Biocept (NASDAQ:BIOC) with a “buy” rating and target price of $1.20. The stock closed at 63 cents on Monday. “Through its proprietary technology platform capable of...

June 7, 2016
Axovant Logo
Markets

Leerink starts Axovant Sciences at outperform

Leerink Partners has launched coverage of Axovant Sciences (NYSE MKT:AXON) with an “outperform” rating and $22 price target. The stock closed at $13.15 on Monday. “We see Axovant as a compelling risk/reward play with...

June 7, 2016
Cempra
Markets

Roth reinitiates coverage of Cempra at buy

Roth Capital Partners has reinitiated coverage of Cempra (NASDAQ:CEMP) with a “buy” rating and $37 price target. The stock closed at $19.48 on Monday. With impressive pivotal studies on solithromycin (Solitaire-IV and...

June 7, 2016